表紙
市場調查報告書

皮下注射生物製劑的全球市場:技術和藥物輸送系統(第3版)、2020年∼2030年

Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030

出版商 ROOTS ANALYSIS 商品編碼 933273
出版日期 內容資訊 英文 536 Pages
商品交期: 最快1-2個工作天內
價格
皮下注射生物製劑的全球市場:技術和藥物輸送系統(第3版)、2020年∼2030年 Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030
出版日期: 2020年04月30日內容資訊: 英文 536 Pages
簡介

生物製劑是現代醫療急速成長的治療用分子之一。 2020年1月公開的報導中提到全球的一年生物製劑市場到2024年為止大約可以達到3,800億美金的規模,與原有的醫療藥品比較下有著更高的成長率(最大8%)。生物製劑主要是可以避免因為胃的代謝而沒有被完全吸收,而由不需口服的方式完成。實際上這種治療法通常都是經由靜脈注射而完成,且需要在醫療現場(醫院/注射中心)實施。現在皮下注射的其他可能正在各個開發階段中,也有非常多的臨床試驗者投入研究。而現在是用靜脈注射方式的治療用品也可能會開發皮下注射的方式。增進粘性藥物製劑的輸送方式與新的技術平台也在開發中。

本報告是以調查並分析全球的皮下注射生物製劑市場病包含市場現況、案例學習、皮下注射的技術市場現況、競爭狀況分析、企業概要、市場現況、經營幹部的訪談等情報資訊。

目錄

第1章 導論

  • 調查範圍
  • 調查方法

第2章 執行摘要

第3章 導論

  • 概要
  • 治療分子的類型
  • 生物來源的治療劑
    • 產品種類
    • 給藥途徑和製劑
    • 皮下注射劑
  • 與法規相關的注意事項
    • 醫療機器
    • 產品與藥物器械結合
  • 未來前景

第4章 皮下注射生物製劑:現在市場情勢

  • 概要
  • 生物製劑皮下注射
  • 皮下注射生物製劑:得到許可的藥物名單
    • 按許可年份分析
    • 按藥理分子類型分析
    • 按治療領域區別分析
    • 按處方種類區別分析
    • 按使用頻率區別分析
    • 按製劑型態區別分析
    • 主要參與者:按批准藥品數量分析
  • 皮下注射生物製劑:臨床候選藥物清單
    • 按發展階段分析
    • 按藥理分子類型分析
    • 按治療領域區別分析
    • 按使用頻率區別
    • 主要參與者:試驗中的候選藥物數量分析

第5章 案例學習:最先端的生物學研究

  • 概要
  • 皮下注射生物製劑:主要藥品按年銷售額
  • 案例學習
    • HUMIRA(Abbey、Eisai)
    • Etanercept(Amgen、Pfizer、武田藥品)
    • RITUXAN/MabThera(Biogen、Roche、中外製藥)
    • Trastuzumab(Roche、中外製藥)
    • Neulasta(Amgen、協和發酵KIRIN)

第6章 皮下製劑技術:現在市場情勢

  • 概要
  • 皮下製劑技術:技術開發企業名單
    • 按成立年份分析
    • 按公司規模分析
    • 按地域區別分析
  • 皮下製劑技術:技術名單
    • 按藥理分子類型分析
    • 投藥途徑分析
    • 按優缺點分析

第7章 皮下處方技術開發公司競爭力分析

  • 概要
  • 皮下處方技術開發公司競爭力分析:競爭環境情況
    • 調查方法
    • 供應商能力、渠道能力、主要優點等三方面分析
  • 皮下製劑技術開發企業:基準分析
    • 調查方法
    • 北美
    • 歐洲

第8章 皮下處方技術開發公司: 企業概說

  • 概要
  • Adocia
    • 公司介紹
    • 技術概要
    • 產品簡介
    • 財務情況
    • 最近動向與前景
  • Ajinomoto Althea
  • Arecor
  • Alteogen
  • Ascendis Pharma
  • Avadel Pharmaceuticals
  • Camurus
  • Creative BioMart
  • Creative Biolabs
  • DURECT
  • Eagle Pharmaceuticals
  • Halozyme Therapeutics
  • MedinCell
  • Xeris Pharmaceuticals
  • Serina Therapeutics

第9章 合作與聯手

  • 概要
  • 合作模式
  • 皮下注射製劑技術:合作與聯手
    • 按照合作年份分析
    • 按照合作方式分析
    • 最活躍的參與者:合作數字分析
    • 地域分析
    • 洲際和洲際協議

第10章 皮下藥物給予系統:現在市場情勢

  • 概要
  • 各種皮下給藥系統
  • 各種皮下給藥系統:全體市場情況
    • 大容量可穿戴注射器
    • 自動注射器
    • 筆型注射
    • 無針注射系統
    • 配方製劑輸送系統
    • 預裝注射器
    • 植入

第11章 SWOT分析

  • 概要
  • SWOT因素的比較
    • 優勢
    • 劣勢
    • 市場機會
    • 威脅

第12章 市場預測與機會分析

  • 概要
  • 皮下注射生物製劑市場
    • 預測調查方法與主要假說
    • 2020年至2030年的全球皮下注射生物製劑市場
  • 皮下給藥系統市場
    • 產品種類1:大容量可穿戴注射器
    • 產品種類2:自動注射器
    • 產品種類3:預裝注射器
    • 產品種類4:無針注射系統
    • 產品種類5:新配方製備系統
  • 皮下製劑技術市場

第13章 結論

第14章 針對經營陣容的考察

第15章 附錄1:圖表數據

第16章 附錄2:公司與組織圖名單

目錄

Example Insights:

Overview:

Biologics represent one of the fastest growing classes of therapeutic molecules in modern healthcare. As per an article published in January 2020, the annual global biologics market is expected to be approximately USD 380 billion by 2024, representing a relatively higher growth rate (~8%) compared to conventional pharmaceuticals. Considering the necessity to bypass gastric metabolism, biologics are mostly designed for administration via parenteral routes. In fact, majority of such therapies are formulated for intravenous delivery and are usually administered in a clinical setting (hospitals / infusion centers). However, this scenario is cost intensive and is known to be associated with medication adherence related concerns. In this context, the subcutaneous route of drug delivery offers a number of benefits, including self-medication and life cycle management options. Although the pharmacokinetic profiles of intravenous and subcutaneous formulations are different, studies have demonstrated that the latter formulations are preferred by end users (patients and healthcare providers), offering substantial cost saving opportunities.

Presently, the subcutaneous delivery option is being investigated for a number of clinical candidates across different phases of development. Moreover, several approved therapeutic products, which are currently available in intravenous dosage forms, are also being reformulated and evaluated for subcutaneous administration. However, there are certain concerns associated with the subcutaneous route. For instance, most protein-based therapeutics, such as monoclonal antibodies, need to be administered in large quantities and have been shown to result in highly viscous formulations when reformulated for subcutaneous delivery. In order to address this particular challenge, many companies have developed / are developing a number of novel technology platforms to facilitate the delivery of viscous drug formulations. Similar innovations are gradually facilitating a shift to subcutaneous delivery, primarily driven by the demand for self-administrable therapeutics. In fact, there are several self-medication solutions, equipped with a variety of user-friendly features, available in the market; examples include prefilled syringes, pen injectors, autoinjectors, needle-free injectors and large volume wearable injectors. Over the past few years, the aforementioned drug-device combination products have witnessed high adoption, enabled substantial reductions in healthcare expenses (incurred by patients), and improved therapy adherence. In this regard, the rising incidence of chronic clinical conditions (which are characterized by the need for frequent medication) and the ongoing efforts of therapy / device developers engaged in this field, are anticipated to drive the growth of the subcutaneous biologics market in the coming years.

Scope of the Report:

The 'Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030' report provides a detailed study on the current market landscape and future potential of biologics designed for subcutaneous administration. In addition, the study provides an in-depth analysis of the formulation technologies and drug delivery systems (focusing on large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, drug reconstitution systems, prefilled syringes and implants) that enable subcutaneous delivery of the biologic drugs. Amongst other elements, the report features the following:

  • A detailed assessment of the current market landscape of commercially available and clinical-stage biologics that are designed for delivery via the subcutaneous route, along with information on approval year, phase of development, type of pharmacological molecule, target therapeutic area, dosing frequency, available dosage forms and key players.
  • A case study on leading subcutaneous biologics (in terms of revenues generated), featuring details on mechanism of action, development history, annual sales, technology platform (if available), and a comparison of their intravenous and subcutaneous formulations (if applicable).
  • An assessment of the various subcutaneous formulation technologies along with information on developers, type of pharmacological molecule, route of administration, mechanisms of action and primary advantage(s).
  • An insightful three-dimensional comparison of the subcutaneous formulation technology developers, based on pipeline strength (number of drugs developed using a particular technology), supplier power (number of years of experience and company size) of the developer and primary advantages offered by their respective technologies. Also, the study includes a detailed benchmark analysis of the technology developers based in North America and Europe, highlighting the primary advantage(s) offered by their proprietary technologies, applicability to other types of pharmacological molecules, and other possible routes of drug administration.
  • Elaborate profiles of key technology developers, featuring a brief overview of the company, its technology portfolio, product portfolio, financial information (if available), recent developments and an informed future outlook.
  • An analysis of collaborations and partnership agreements inked by the subcutaneous formulation technology developers since 2011; it includes details of deals that were / are focused on subcutaneous formulation technologies, which were analyzed on the basis of year of agreement, type of agreement, and upfront and milestone payments.
  • An in-depth review of the most advanced and popular subcutaneous drug delivery systems, including large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, drug reconstitution systems, prefilled syringes and implants, providing information on their developer(s) and device specific features. Details of specific parameters captured for different device categories are mentioned as follows:
  • Large volume wearable injectors: Stage of development (commercialized and under development), type of device (infusion pump and patch pump), type of dose administered (continuous and bolus), volume / storage capacity (in mL), mode of injection (needle, needle / cannula and needle / catheter) and mechanism of action (driving force).
  • Autoinjectors: Usability (disposable and reusable), type of primary container (syringe, cartridge and others), volume / storage capacity (in mL), type of dose (fixed dose and variable dose) and actuation mechanism (automatic, semi-automatic and manual).
  • Pen injectors: Usability (disposable and reusable), volume / storage capacity (in mL), and type of dose (fixed dose and variable dose).
  • Needle-free injection systems: Stage of development (commercialized and under development), volume / storage capacity (in mL), usability (disposable and reusable), and actuation mechanism (spring-based, gas-powered and others).
  • Drug reconstitution systems: Usability (disposable and reusable), device type (dual chambered systems and other novel systems) and type of drug container (cartridge, vials and others).
  • Prefilled syringes: Barrel fabrication material (glass and plastic), number of barrel chambers (single chamber and dual chamber), type of needle system (fixed needle system, luer lock and luer cone) and volume / storage capacity (in mL).
  • Implants: Stage of development (commercialized and under development), target therapeutic area, implant material (silicone, titanium, polymers and others) and treatment duration.
  • A comprehensive product competitiveness analysis of subcutaneous large volume wearable injectors, subcutaneous autoinjectors, subcutaneous needle-free injectors and pre-filled syringes, taking into consideration the supplier power and product specific information.
  • A discussion on affiliated trends, key drivers and challenges, which are likely to impact the industry's evolution, under a comprehensive SWOT framework; it includes a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall subcutaneous products market.

One of the key objectives of this study was to understand the primary growth drivers and estimate the existing market size and the future growth potential of the subcutaneous biologics, technologies and drug delivery systems market. Based on historical trends and sales related information for subcutaneous biologic drugs, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] phase of development (approved, preregistration & phase III and phase II & phase II/III)), [B] type of pharmacological molecule (proteins, peptides (recombinant), monoclonal antibodies, other antibody based products, cell / gene therapies and vaccines), [C] target therapeutic areas (autoimmune disorders, metabolic disorders, blood disorders, bone disorders, oncological disorders, genetic disorders, neurological disorders, respiratory disorders and other disorders) and [D] key geographical regions (North America, Europe, Asia-Pacific and rest of the world). In addition to the market forecast for subcutaneous biologic drugs, we have also provided a 10-year forecast for subcutaneous delivery systems, covering the market for large volume wearable injectors, autoinjectors, prefilled syringes, needle-free injectors and drug reconstitution systems. Further, we have also forecasted the revenues that subcutaneous formulation technology developers are likely to generate through licensing agreements; for this, we have provided a view on the likely upfront payments and milestone payments that will be generated from the deals related to the development of subcutaneous formulation of biologics. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Deborah Bitterfield (Chief Executive Officer and Founder, Lindy Biosciences)
  • Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies)
  • Steve Prestrelski (Chief Scientific Officer and Founder, Xeris Pharmaceuticals), Hong Qi ( Vice President, Product Development, Xeris Pharmaceuticals) and Scott Coleman (Sr. Scientist Formulation, Xeris Pharmaceuticals)
  • David Daily (Chief Executive Officer and Co-Founder, DALI Medical Devices)
  • Michael Reilly (Chief Executive Officer and Co-Founder, Excelse Bio)
  • Poonam R Velagaleti (Co-Founder, i-novion)
  • Michael Hooven (Chief Executive Officer, Enable Injections)
  • Frederic Ors (Chief Executive Officer, Immunovaccine Technologies)
  • Patrick Anquetil (Chief Executive Officer, Portal Instruments)
  • Menachem Zucker (Vice President and Chief Scientist, Elcam Medical)
  • Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services) and Graham Reynolds (Vice President and General Manager, Global Biologics, West Pharmaceutical Services)
  • David Heuzé (Communication Leader, MedinCell)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified

Chapter Outlines:

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the subcutaneous biologics, technologies and drug delivery systems market, in the short to mid and long term.

Chapter 3 provides a general introduction to the various types of therapeutic molecules (biologics and small molecules) comparing their characteristics, such as molecular size, molecule structure, immunogenicity and stability. The chapter also highlights different types of biologically derived products that are currently being developed by various stakeholders in this industry. It further discusses the challenges associated with the parenteral route of drug delivery, specifically, those related to the traditional intravenous (infusion) route. Further, the chapter features a discussion on the different routes of administration, specifically focusing on the subcutaneous route, highlighting its advantages and associated limitations.

Chapter 4 includes information on over 450 subcutaneous biologic drug candidates that are currently approved / being developed. It features a comprehensive analysis of marketed and clinical-stage biologics based on the approval year, phase of development type of pharmacological molecule, target therapeutic area, dosing frequency, available dosage forms and key players.

Chapter 5 is a collection of case studies on the leading subcutaneous biologics, in terms of the annual global sales. Each case study includes drug / therapy specifications, their respective mechanism of action, development history, annual sales, technology platform (if available), and a comparison of their intravenous and subcutaneous formulations (if applicable).

Chapter 6 provides a list of subcutaneous formulation technologies that are currently available / being developed by various firms in this domain. The chapter highlights key features of each technology and provides information on their developers. It also features an analysis based on the type of pharmacological molecule, route of administration, mechanisms of action and primary advantage(s).

Chapter 7 features a three-dimensional comparison of the subcutaneous formulation technology developers, based on pipeline strength (number of drugs developed using a particular technology), supplier power (number of years of experience and company size) of the developer and primary advantages offered by their respective technologies. It also includes a benchmark analysis of technology developers that are based in North America and Europe, highlighting the advantage(s) of their proprietary technologies, applicability to other types of pharmacological molecules, and other possible routes of drug administration

Chapter 8 includes elaborate profiles of key technology developers, featuring overview of the company, its technology portfolio, product portfolio, financial information (if available), recent developments and an informed future outlook.

Chapter 9 features an elaborate analysis and discussion of the various collaborations and partnerships related to the subcutaneous formulation technologies, which have been inked amongst players. It includes a brief description of the purpose of the partnership models (including licensing agreements, mergers / acquisitions, product development, service alliances, manufacturing, and others) that have been adopted by the stakeholders in this domain, since 2011. It consists of a schematic representation showcasing the players that have forged the maximum number of alliances. Furthermore, we have provided a world map representation of the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 10 features an elaborate discussion on subcutaneous delivery systems with special focus on large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, drug reconstitution systems, prefilled syringes and implants. It includes a detailed analysis based on specific parameters for each device category, namely [A] large volume wearable injectors, by stage of development (commercialized and under development), type of device (infusion pump and patch pump), type of dose administered (continuous and bolus), volume / storage capacity (in mL), mode of injection (needle, needle / cannula and needle / catheter) and mechanism of action (driving force), [B] autoinjectors, by usability (disposable and reusable), type of primary container (syringe, cartridge and others), volume / storage capacity (in mL), type of dose (fixed dose and variable dose) and actuation mechanism (automatic, semi-automatic and manual), [C] pen-injectors, by usability (disposable and reusable), volume / storage capacity (in mL), and type of dose (fixed dose and variable dose), [D] needle-free injection systems, by stage of development (commercialized and under development), volume / storage capacity (in mL), usability (disposable and reusable), and actuation mechanism (spring-based, gas-powered and others), [E] drug reconstitution systems, by usability (disposable and reusable), device type (dual chambered systems and other novel systems) and type of drug container (cartridge, vials and others), [F] prefilled syringes, by barrel fabrication material (glass and plastic), number of barrel chambers (single chamber and dual chamber), type of needle system (fixed needle system, luer lock and luer cone) and volume / storage capacity (in mL), and [G] implants, by stage of development (commercialized and under development), target therapeutic area, implant material (silicone, titanium, polymers and others) and treatment duration. As large volume wearable injectors, pre-filled syringes, needle-free injectors and autoinjectors represent the most novel and advanced types of devices, we have also provided a comprehensive product competitiveness analysis of these products taking into consideration the supplier power (based on size of employee base) and product specifications.

Chapter 11 provides a detailed analysis capturing the key parameters and trends that are likely to impact the industry's evolution, under a comprehensive SWOT framework; it includes a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall subcutaneous products market.

Chapter 12 presents an informed estimate of the current and future opportunity in the subcutaneous biologics, technologies and drug delivery systems market, highlighting the likely growth of the market till the year 2030. It also includes future sales projections of various subcutaneous biologic drug candidates that are currently being evaluated by different players. The chapter presents a detailed market segmentation on the basis of phase of development (approved, preregistration & phase III and phase II and phase II/III), type of pharmacological molecule (proteins, peptides (recombinant), monoclonal antibodies, other antibody based products, cell / gene therapies and vaccines), target therapeutic areas (autoimmune disorders, metabolic disorders, blood disorders, bone disorders, oncological disorders, genetic disorders, neurological disorders, respiratory disorders and other disorders) and key geographical regions (North America, Europe, Asia-Pacific and rest of the world). In addition to the market forecast for subcutaneous biologic drugs, we have also provided a 10-year forecast for subcutaneous delivery systems, covering the market for large volume wearable injectors, autoinjectors, prefilled syringes, needle-free injectors, drug reconstitution systems. Further, we have also forecasted the revenues that subcutaneous formulation technology developers are likely to generate through licensing agreements; for this, we have provided a view on the likely upfront payments and milestone payments that will be generated from the deals related to the development of subcutaneous formulation of biologics.

Chapter 13 is a summary of the overall report. In this chapter, we have provided a list of the key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 14 is a collection of interview transcripts of discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with Deborah Bitterfield (Chief Executive Officer and Founder, Lindy Biosciences), Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies), Steve Prestrelski (Chief Scientific Officer and Founder, Xeris Pharmaceuticals), Hong Qi ( Vice President, Product Development, Xeris Pharmaceuticals) and Scott Coleman (Sr. Scientist Formulation, Xeris Pharmaceuticals), David Daily (Chief Executive Officer and Co-Founder, DALI Medical Devices), Michael Reilly (Chief Executive Officer and Co-Founder, Excelse Bio), Poonam R Velagaleti (Co-Founder, i-novion), Michael Hooven (Chief Executive Officer, Enable Injections), Frederic Ors (Chief Executive Officer, Immunovaccine Technologies), Patrick Anquetil (Chief Executive Officer, Portal Instruments), Menachem Zucker (Vice President and Chief Scientist, Elcam Medical), Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services) and Graham Reynolds (Vice President and General Manager, Global Biologics, West Pharmaceutical Services) and David Heuzé (Communication Leader, MedinCell).

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 16 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Types of Therapeutic Molecules
  • 3.3. Biologically Derived Therapeutics
    • 3.3.1. Types of Products
    • 3.3.2. Routes of Administration and Formulations
    • 3.3.3. Subcutaneous Formulations
      • 3.3.3.1. Approaches in Subcutaneous Delivery of Biologics
        • 3.3.3.1.1. Reformulation
        • 3.3.3.1.2. Differing Potencies
        • 3.3.3.1.3. Novel Technologies
      • 3.3.3.2. Method of Subcutaneous Administration
      • 3.3.3.3. Advantages of Subcutaneous Administration
      • 3.3.3.4. Limitations of Subcutaneous Administration
  • 3.4. Regulatory Considerations
    • 3.4.1. Medical Devices
    • 3.4.2. Drug Device Combination Products
  • 3.5. Future Perspectives

4. SUBCUTANEOUS BIOLOGICS: CURRENT MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Subcutaneous Administration of Biologics
  • 4.3. Subcutaneous Biologics: List of Approved Drugs
    • 4.3.1. Analysis by Approval Year
    • 4.3.2. Analysis by Type of Pharmacological Molecule
    • 4.3.3. Analysis by Target Therapeutic Area
    • 4.3.4. Analysis by Type of Formulation
    • 4.3.5. Analysis by Dosing Frequency
    • 4.3.6. Analysis by Dosage Form
    • 4.3.7. Key Players: Analysis by Number of Drugs Approved
  • 4.4. Subcutaneous Biologics: List of Clinical-Stage Drug Candidates
    • 4.4.1. Analysis by Phase of Development
    • 4.4.2. Analysis by Type of Pharmacological Molecule
    • 4.4.3. Analysis by Target Therapeutic Area
    • 4.4.4. Analysis by Dosing Frequency
    • 4.4.5. Key Players: Analysis by Number of Drug Candidates in Trials

5. CASE STUDY: LEADING SUBCUTANEOUS BIOLOGICS

  • 5.1. Chapter Overview
  • 5.2. Subcutaneous Biologics: Leading Drugs by Annual Sales
  • 5.3. Case Studies
    • 5.3.1. HUMIRA® (AbbVie, Eisai)
      • 5.3.1.1. Drug Overview
      • 5.3.1.2. Development History
      • 5.3.1.3. Target Indications and Dosage Forms
      • 5.3.1.4. Historical Sales
    • 5.3.2. Enbrel® (Amgen, Pfizer, Takeda Pharmaceutical)
      • 5.3.2.1. Overview
      • 5.3.2.2. Development History
      • 5.3.2.3. Target Indications and Dosage Forms
      • 5.3.2.4. Historical Sales
    • 5.3.3. RITUXAN® / MabThera® (Biogen, Roche, Chugai Pharmaceutical)
      • 5.3.3.1. Overview
      • 5.3.3.2. Development History
      • 5.3.3.3. Target Indications and Dosage Forms
      • 5.3.3.4. Historical Sales
      • 5.3.3.5. ENHANZE™ Technology (Halozyme Therapeutics)
      • 5.3.3.6. Advantages of Subcutaneous RITUXAN® / MabThera® Over Intravenous RITUXAN® / MabThera®
    • 5.3.4. Herceptin® (Roche, Chugai Pharmaceutical)
      • 5.3.4.1. Overview
      • 5.3.4.2. Development History
      • 5.3.4.3. Target Indications and Dosage Forms
      • 5.3.4.4. Historical Sales
      • 5.3.4.5. ENHANZE™ Technology (Halozyme Therapeutics)
      • 5.3.4.6. Advantages of Subcutaneous Herceptin® Over Intravenous Herceptin®
      • 5.3.4.7. Herceptin® - Large Volume Wearable Injector Combination Product
    • 5.3.5. Neulasta® (Amgen, Kyowa Hakko Kirin)
      • 5.3.5.1. Overview
      • 5.3.5.2. Development History
      • 5.3.5.3. Target Indications and Dosage Forms
      • 5.3.5.4. Historical Sales

6. SUBCUTANEOUS FORMULATION TECHNOLOGIES: CURRENT MARKET LANDSCAPE

  • 6.1. Chapter Overview
  • 6.2. Subcutaneous Formulation Technologies: List of Technology Developers
    • 6.2.1. Analysis by Year of Establishment
    • 6.2.2. Analysis by Company Size
    • 6.2.3. Analysis by Geographical Location
  • 6.3. Subcutaneous Formulation Technologies: List of Technologies
    • 6.3.1. Analysis by Type of Pharmacological Molecule
    • 6.3.2. Analysis by Route of Administration
    • 6.3.3. Analysis by Advantage(s) Offered

7. SUBCUTANEOUS FORMULATION TECHNOLOGY DEVELOPERS: COMPANY COMPETITIVENESS ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Subcutaneous Formulation Technology Developers: Competitive Landscape
    • 7.2.1. Methodology
    • 7.2.2. Three-Dimensional Bubble Analysis based on Supplier Power, Pipeline Strength and Primary Advantage(s)
  • 7.3. Subcutaneous Formulation Technology Developers: Benchmark Analysis
    • 7.3.1. Methodology
    • 7.3.2. North America
    • 7.3.3. Europe

8. SUBCUTANEOUS FORMULATION TECHNOLOGY DEVELOPERS: COMPANY PROFILES

  • 8.1. Chapter Overview
  • 8.2. Adocia
    • 8.2.1. Company Overview
    • 8.2.2. Technology Overview
      • 8.2.2.1. BioChaperone® Technology
    • 8.2.3. Product Portfolio
    • 8.2.4. Financial Performance
    • 8.2.5. Recent Developments and Future Outlook
  • 8.3. Ajinomoto Althea
    • 8.3.1. Company Overview
    • 8.3.2. Technology Overview
      • 8.3.2.1. Crystalomics® Formulation Technology
    • 8.3.3. Product Portfolio
    • 8.3.4. Financial Performance
    • 8.3.5. Recent Developments and Future Outlook
  • 8.4. Arecor
    • 8.4.1. Company Overview
    • 8.4.2. Technology Overview
      • 8.4.2.1. Arestat™ Technology
    • 8.4.3. Product Portfolio
    • 8.4.4. Recent Developments and Future Outlook
  • 8.5. Alteogen
    • 8.5.1. Company Overview
    • 8.5.2. Technology Overview
      • 8.5.2.1. Hybrozyme Technology
    • 8.5.3. Product Portfolio
    • 8.5.4. Recent Developments and Future Outlook
  • 8.6. Ascendis Pharma
    • 8.6.1. Company Overview
    • 8.6.2. Technology Overview
      • 8.6.2.1. TransCon Technology
    • 8.6.3. Product Portfolio
    • 8.6.4. Financial Performance
    • 8.6.5. Recent Developments and Future Outlook
  • 8.7. Avadel Pharmaceuticals
    • 8.7.1. Company Overview
    • 8.7.2. Technology Overview
      • 8.7.2.1. Medusa™ Technology
    • 8.7.3. Product Portfolio
    • 8.7.4. Financial Performance
    • 8.7.5. Recent Developments and Future Outlook
  • 8.8. Camurus
    • 8.8.1. Company Overview
    • 8.8.2. Technology Overview
      • 8.8.2.1. FluidCrystal® Injection Depot Technology
    • 8.8.3. Product Portfolio
    • 8.8.4. Financial Performance
    • 8.8.5. Recent Developments and Future Outlook
  • 8.9. Creative BioMart
    • 8.9.1. Company Overview
    • 8.9.2. Technology Overview
      • 8.9.2.1. High Concentration Formulation Technology
    • 8.9.3. Product Portfolio
    • 8.9.4. Recent Developments and Future Outlook
  • 8.10. Creative Biolabs
    • 8.10.1. Company Overview
    • 8.10.2. Technology Overview
      • 8.10.2.1. Long-Acting Injectable Technology
    • 8.10.3. Product Portfolio
    • 8.10.4. Recent Developments and Future Outlook
  • 8.11. DURECT
    • 8.11.1. Company Overview
    • 8.11.2. Technology Overview
      • 8.11.2.1. SABER® Platform
      • 8.11.2.2. CLOUD™ PLATFORM
    • 8.11.3. Product Portfolio
    • 8.11.4. Financial Performance
    • 8.11.5. Recent Developments and Future Outlook
  • 8.12. Eagle Pharmaceuticals
    • 8.12.1. Company Overview
    • 8.12.2. Technology Overview
      • 8.12.2.1. Unnamed Technology
    • 8.12.3. Product Portfolio
    • 8.12.4. Financial Performance
    • 8.12.5. Recent Developments and Future Outlook
  • 8.13. Halozyme Therapeutics
    • 8.13.1. Company Overview
    • 8.13.2. Technology Overview
      • 8.13.2.1. ENHANZE® Technology
    • 8.13.3. Product Portfolio
    • 8.13.4. Financial Performance
    • 8.13.5. Recent Developments and Future Outlook
  • 8.14. MedinCell
    • 8.14.1. Company Overview
    • 8.14.2. Technology Overview
      • 8.14.2.1. BEPO® Technology
    • 8.14.3. Product Portfolio
    • 8.14.4. Recent Developments and Future Outlook
  • 8.15. Xeris Pharmaceuticals
    • 8.15.1. Company Overview
    • 8.15.2. Technology Overview
      • 8.15.2.1. XeriJect™ Technology
      • 8.15.2.2. XeriSol™ Technology
    • 8.15.3. Product Portfolio
    • 8.15.4. Recent Developments and Future Outlook
  • 8.16. Serina Therapeutics
    • 8.16.1. Company Overview
    • 8.16.2. Technology Overview
      • 8.16.2.1. POZ™ Drug Delivery Technology
    • 8.16.3. Product Portfolio
    • 8.16.4. Recent Developments and Future Outlook

9. PARTNERSHIPS AND COLLABORATIONS

  • 9.1. Chapter Overview
  • 9.2. Partnership Models
  • 9.3. Subcutaneous Formulation Technologies: Partnerships and Collaborations
    • 9.3.1. Analysis by Year of Partnership
    • 9.3.2. Analysis by Type of Partnership
    • 9.3.3. Most Active Players: Analysis by Number of Partnerships
    • 9.3.4. Regional Analysis
    • 9.3.5. Intercontinental and Intracontinental Agreements

10. SUBCUTANEOUS DRUG DELIVERY SYSTEMS: CURRENT MARKET LANDSCAPE

  • 10.1. Chapter Overview
  • 10.2. Different Types of Subcutaneous Drug Delivery Systems
  • 10.3. Subcutaneous Drug Delivery Systems: Overall Market Landscape
    • 10.3.1. Large Volume Wearable Injectors
      • 10.3.1.1. Overview
      • 10.3.1.2. Current Market Landscape of Devices for Non-insulin Biologics
        • 10.3.1.2.1. Analysis by Stage of Development
        • 10.3.1.2.2. Analysis by Type of Device
        • 10.3.1.2.3. Analysis by Type of Dose Administered
        • 10.3.1.2.4. Analysis by Volume / Storage Capacity
        • 10.3.1.2.5. Analysis by Usability
        • 10.3.1.2.6. Analysis by Mode of Injection
        • 10.3.1.2.7. Analysis by Mechanism of Action
        • 10.3.1.2.8. Most Active Players: Analysis by Number of Devices
        • 10.3.1.2.9. Product Competitiveness Analysis
      • 10.3.1.3. Current Market Landscape of Devices for Insulin10.3.1.3.1.Analysis by Stage of Development
        • 10.3.1.3.2. Analysis by Type of Device
        • 10.3.1.3.3. Analysis by Volume / Storage Capacity
        • 10.3.1.3.4. Analysis by Usability
        • 10.3.1.3.5. Analysis by Availability of Integrated CGM / BGM System
        • 10.3.1.3.6. Most Active Players: Analysis by Number of Devices
        • 10.3.1.3.7 Product Competitiveness Analysis
    • 10.3.2. Autoinjectors
      • 10.3.2.1. Overview
      • 10.3.2.2. Current Market Landscape
        • 10.3.2.2.1. Analysis by Usability
        • 10.3.2.2.2. Analysis by Type of Primary Container
        • 10.3.2.2.3. Analysis by Volume / Storage Capacity
        • 10.3.2.2.4. Analysis by Type of Dose
        • 10.3.2.2.5. Analysis by Actuation Mechanism
        • 10.3.2.2.6. Most Active Players: Analysis by Number of Devices
        • 10.3.2.2.7. Product Competitiveness Analysis
      • 10.3.2.3. Drug Device Combination Products
    • 10.3.3. Pen Injectors
      • 10.3.3.1. Overview
      • 10.3.3.2. Current Market Landscape
        • 10.3.3.2.1. Analysis by Usability
        • 10.3.3.2.2. Analysis by Volume / Storage Capacity
        • 10.3.3.2.3. Analysis by Type of Dose
        • 10.3.3.2.4. Most Active Players: Analysis by Number of Devices
      • 10.3.3.3. Drug Device Combination Products
    • 10.3.4. Needle-Free Injection Systems
      • 10.3.4.1. Overview
      • 10.3.4.2. Current Market Landscape
        • 10.3.4.2.1. Analysis by Stage of Development
        • 10.3.4.2.2. Analysis by Volume / Storage Capacity
        • 10.3.4.2.3. Analysis by Usability
        • 10.3.4.2.4. Analysis by Actuation Mechanism
        • 10.3.4.2.5. Most Active Players: Analysis by Number of Devices
        • 10.3.4.2.6. Product Competitiveness Analysis
    • 10.3.5. Drug Reconstitution Delivery Systems
      • 10.3.5.1. Overview
      • 10.3.5.2. Current Market Landscape
        • 10.3.5.2.1. Analysis by Usability
        • 10.3.5.2.2. Analysis by Type of Device
        • 10.3.5.2.3. Analysis by Type of Drug Container
        • 10.3.5.2.4. Most Active Players: Analysis by Number of Devices
    • 10.3.6. Prefilled Syringes
      • 10.3.6.1. Overview
      • 10.3.6.2. Current Market Landscape
        • 10.3.6.2.1. Analysis by Barrel Fabrication Material
        • 10.3.6.2.2. Analysis by Number of Barrel Chambers
        • 10.3.6.2.3. Analysis by Type of Needle System
        • 10.3.6.2.4. Analysis by Volume / Storage Capacity
        • 10.3.6.3.5. Most Active Players: Analysis by Number of Devices
      • 10.3.6.3. Product Competitiveness Analysis
      • 10.3.6.4. Drug Device Combination Products
    • 10.3.7. Implants
      • 10.3.7.1. Overview
      • 10.3.7.2. Current Market Landscape
        • 10.3.7.2.1. Analysis by Stage of Development
        • 10.3.7.2.2. Analysis by Target Therapeutic Area
        • 10.3.7.2.3. Analysis by Implant Material
        • 10.3.7.2.4. Analysis by Treatment Duration
        • 10.3.7.2.5. Most Active Players: Analysis by Number of Devices

11. SWOT ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Comparison of SWOT Factors
    • 11.2.1. Strengths
    • 11.2.2. Weaknesses
    • 11.2.3. Opportunities
    • 11.2.4. Threats

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Subcutaneous Biologics Market
    • 12.2.1. Forecast Methodology and Key Assumptions
    • 12.2.2. Overall Subcutaneous Biologics Market, 2020-2030
      • 12.2.2.1. Subcutaneous Biologics Market, 2020-2030:Distribution by Phase of Development
      • 12.2.2.2. Subcutaneous Biologics Market, 2020-2030:Distribution by Type of Pharmacological Molecule
      • 12.2.2.3. Subcutaneous Biologics Market, 2020-2030:Distribution by Target Therapeutic Area
      • 12.2.2.4. Subcutaneous Biologics Market, 2020-2030:Distribution by Key Geographical Regions
  • 12.3. Subcutaneous Drug Delivery Systems Market
    • 12.3.1. Device Type 1: Large Volume Wearable Injectors
      • 12.3.1.1. Forecast Methodology and Key Assumptions
      • 12.3.1.2. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2020-2030
        • 12.3.1.2.1. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2020-2030
        • 12.3.1.2.2. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2020-2030
        • 12.3.1.2.3. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Target Therapeutic Area, 2020-2030
        • 12.3.1.2.4. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Key Geographical Regions, 2020-2030
      • 12.3.1.3. Global Large Volume Wearable Injectors Market for Insulin , 2020-2030
        • 12.3.1.3.1. Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, 2020-2030
        • 12.3.1.3.2. Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, 2020-2030
        • 12.3.1.3.3. Global Large Volume Wearable Injectors Market for Insulin: Distribution by Key Geographical Regions, 2020-2030
    • 12.3.2. Device Type 2: Autoinjectors
      • 12.3.2.1. Forecast Methodology and Key Assumptions
      • 12.3.2.2. Global Autoinjectors Market, 2020-2030
        • 12.3.2.2.1. Global Autoinjectors Market: Distribution by Usability, 2020-2030
        • 12.3.2.2.2. Global Autoinjectors Market: Distribution by Type of Pharmacological Molecule, 2020-2030
        • 12.3.2.2.3. Global Autoinjectors Market: Distribution by Key Geographical Regions, 2020-2030
    • 12.3.3. Device Type 3: Prefilled Syringes
      • 12.3.3.1. Forecast Methodology and Key Assumptions
      • 12.3.3.2. Global Prefilled Syringes Market, 2020-2030
        • 12.3.3.2.1. Global Prefilled Syringes Market: Distribution by Type of Syringe Barrel Material, 2020-2030
        • 12.3.3.2.2. Global Prefilled Syringes Market: Distribution by Type of Chamber System, 2020-2030
        • 12.3.3.2.3. Global Prefilled Syringes Market: Distribution by Type of Pharmacological Molecule, 2020-2030
        • 12.3.3.2.4. Global Prefilled Syringes Market: Distribution by Target Therapeutic Area, 2020-2030
        • 12.3.3.2.5. Global Prefilled Syringes Market: Distribution by Key Geographical Regions, 2020-2030
    • 12.3.4. Device Type 4: Needle-Free Injection Systems
      • 12.3.4.1. Forecast Methodology and Key Assumptions
      • 12.3.4.2. Global Needle-Free Injection Systems Market, 2020-2030
        • 12.3.4.2.1. Global Needle-Free Injection Systems Market: Distribution by Usability, 2020-2030
        • 12.3.4.2.2. Global Needle-Free Injection Systems Market: Distribution by Actuation Mechanism, 2020-2030
        • 12.3.4.2.3. Global Needle-Free Injection Systems Market: Distribution by Target Therapeutic Area, 2020-2030
        • 12.3.4.2.4. Global Needle-Free Injection Systems Market: Distribution by Key Geographical Regions, 2020-2030
    • 12.3.5. Device Type 5: Novel Drug Reconstitution Systems
      • 12.3.5.1. Forecast Methodology and Key Assumptions
      • 12.3.5.2. Global Novel Drug Reconstitution Systems Market, 2020-2030
  • 12.4. Subcutaneous Formulation Technologies Market
    • 12.4.1. Subcutaneous Formulation Technologies Market: Distribution by Upfront and Milestone Payments, 2020-2030

13. CONCLUDING REMARKS

14. EXECUTIVE INSIGHTS

  • 14.1. Chapter Overview
  • 14.2. Lindy Biosciences
    • 14.2.1. Company Snapshot
    • 14.2.2. Interview Transcript: Deborah Bitterfield, Chief Executive Officer and Founder
  • 14.3. Oval Medical Technologies
    • 14.3.1. Company Snapshot
    • 14.3.2. Interview Transcript: Matthew Young, Chief Technology Officer and Founder
  • 14.4. Xeris Pharmaceuticals
    • 14.4.1. Company Snapshot
    • 14.4.2. Interview Transcript: Steve Prestrelski, Chief Scientific Officer and Founder; Hong Qi, Vice President, Product Development; and Scott Coleman, Sr. Scientist Formulation)
  • 14.5. DALI Medical Devices
    • 14.5.1. Company Snapshot
    • 14.5.2. Interview Transcript: David Daily, Chief Executive Officer and Co-Founder
  • 14.6. Excelse Bio
    • 14.6.1. Company Snapshot
    • 14.6.2. Interview Transcript: Michael Reilly, Chief Executive Officer and Co-Founder
  • 14.7. i-novion
    • 14.7.1. Company Snapshot
    • 14.7.2. Interview Transcript: Poonam R Velagaleti, Co-Founder
  • 14.8. Enable Injections
    • 14.8.1. Company Snapshot
    • 14.8.2. Interview Transcript: Michael Hooven, Chief Executive Officer
  • 14.9. Immunovaccine Technologies
    • 14.9.1. Company Snapshot
    • 14.9.2. Interview Transcript: Frederic Ors, Chief Executive Officer
  • 14.10. Portal Instruments
    • 14.10.1. Company Snapshot
    • 14.10.2. Interview Transcript: Patrick Anquetil, Chief Executive Officer
  • 14.11. Elcam Medical
    • 14.11.1. Company Snapshot
    • 14.11.2. Interview Transcript: Menachem Zucker, Vice President and Chief Scientist
  • 14.12. West Pharmaceutical Services
    • 14.12.1. Company Snapshot
    • 14.12.2. Interview Transcript: Tiffany H Burke, Director, Global Communications and Graham Reynolds, Vice President and General Manager, Global Biologics
  • 14.13. MedinCell
    • 14.13.1. Company Snapshot
    • 14.13.2. Interview Transcript: David Heuzé, Communication Leader

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

List Of Figures

  • Figure 3.1 Types of Biologically Derived Therapeutic Molecules
  • Figure 3.2 Intravenous to Subcutaneous Formulations: Key Considerations
  • Figure 3.3 Intravenous to Subcutaneous Formulations: Development Process
  • Figure 3.4 Subcutaneous Drug Delivery: Possible Routes of Administration for Large-Dose Biologics
  • Figure 3.5 Large Volume Subcutaneous Drug Delivery Devices
  • Figure 3.6 Key Steps in Subcutaneous Drug Delivery
  • Figure 4.1 Approved Subcutaneous Biologics: Distribution by Approval Year
  • Figure 4.2 Approved Subcutaneous Biologics: Distribution by Type of Pharmacological Molecule
  • Figure 4.3 Approved Subcutaneous Biologics: Distribution by Target Therapeutic Area
  • Figure 4.4 Approved Subcutaneous Biologics: Distribution by Formulation
  • Figure 4.5 Approved Subcutaneous Biologics: Distribution by Dosing Frequency
  • Figure 4.6 Approved Subcutaneous Biologics: Distribution by Dosage Form
  • Figure 4.7 Key Players: Distribution by Number of Drugs Approved
  • Figure 4.8 Clinical-Stage Subcutaneous Biologics: Distribution by Phase of Development
  • Figure 4.9 Clinical-Stage Subcutaneous Biologics: Distribution by Type of Pharmacological Molecule
  • Figure 4.10 Clinical-Stage Subcutaneous Biologics: Distribution by Target Therapeutic Area
  • Figure 4.11 Clinical-Stage Subcutaneous Biologics: Distribution by Dosing Frequency
  • Figure 4.12 Key Players: Distribution by Number of Clinical-Stage Subcutaneous Biologics
  • Figure 5.1 Subcutaneous Biologics: Leading Drugs by Annual Sales, 2019 (USD Billion)
  • Figure 5.2 HUMIRA®: Approval Timeline (US, EU and Japan)
  • Figure 5.3 HUMIRA®: Approval Timeline for Various Dosage Forms (US and EU)
  • Figure 5.4 HUMIRA®: Annual Sales, 2003-2019 (USD Billion)
  • Figure 5.5 Enbrel®: Approval Timeline for Various Dosage Forms (US and EU)
  • Figure 5.6 Enbrel®: Annual Sales in the US and Canada, 2002-2019 (USD Billion)
  • Figure 5.7 Enbrel®: Annual Sales Outside US and Canada, 2010-2019 (USD Billion)
  • Figure 5.8 RITUXAN® / MabThera®: Annual Sales, 1999-2019 (CHF Billion)
  • Figure 5.9 Herceptin®: Annual Sales, 1999-2019 (CHF Billion)
  • Figure 5.10 Neulasta®: Annual Sales, 2005-2019 (USD Billion)
  • Figure 6.1 High Concentration Protein Formulations: Advantages
  • Figure 6.2 High Concentration Protein Formulations: Associated Challenges
  • Figure 6.3 Subcutaneous Formulation Technologies: Distribution by Year of Establishment
  • Figure 6.4 Subcutaneous Formulation Technologies: Distribution by Company Size
  • Figure 6.5 Subcutaneous Formulation Technologies: Distribution by Geographical Location
  • Figure 6.6 Subcutaneous Formulation Technologies: Distribution by Type of Pharmacological Molecule
  • Figure 6.7 Subcutaneous Formulation Technologies: Distribution by Route of Administration
  • Figure 6.8 Subcutaneous Formulation Technologies: Distribution by Advantage(s) Offered
  • Figure 6.9 Logo Landscape: Distribution by Primary Advantage(s) Offered and Company Size of Developer
  • Figure 7.1 Company Competitiveness Analysis: Three-Dimensional Bubble Chart based on Supplier Power, Pipeline Strength and Primary Advantage(s)
  • Figure 7.2 Benchmark Analysis: Subcutaneous Formulation Technology Developers based in North America
  • Figure 7.3 Benchmark Analysis: Subcutaneous Formulation Technology Developers based
  • Figure 8.1 Adocia: Annual Revenues, 2014-2019 (EUR Million)
  • Figure 8.2 Ajinomoto Althea: Service Portfolio
  • Figure 8.3 Ajinomoto Althea: Crystalomics® Technology (Process Steps)
  • Figure 8.4 Ajinomoto: Annual Revenues, FY1213-FY1819 (JPY Billion)
  • Figure 8.5 Arecor: Arestat™ Technology (Advantages)
  • Figure 8.6 Ascendis Pharma: Annual Revenues, 2012-Q3 2019 (EUR Million)
  • Figure 8.7 Avadel Pharmaceuticals: Medusa™ Technology (Process Steps)
  • Figure 8.8 Avadel Pharmaceuticals: Annual Revenues, 2013-2019 (USD Million)
  • Figure 8.9 Camurus: FluidCrystal® Injection Depot Technology (Process Steps)
  • Figure 8.10 Camurus: Annual Revenues, 2013-Q1 2019 (SEK Million)
  • Figure 8.11 DURECT: Annual Revenues, 2015-2019 (USD Million)
  • Figure 8.12 Eagle Pharmaceuticals: Annual Revenues, 2015-2019 (USD Million)
  • Figure 8.13 Halozyme Therapeutics: Annual Revenues, 2009-2018 (USD Million)
  • Figure 8.14 MedinCell: BEPO® Technology (Process Steps)
  • Figure 8.15 Xeris Pharmaceuticals: XeriJect™ Technology (Process Steps)
  • Figure 8.16 Xeris Pharmaceuticals: XeriSol™ Technology (Process Steps)
  • Figure 9.1 Partnerships and Collaborations: Cumulative Distribution by Year of Partnership, 2011-2020
  • Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 9.3 Most Active Players: Distribution by Number of Partnerships
  • Figure 9.4 Partnerships and Collaborations: Regional Distribution
  • Figure 9.5 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Figure 10.1 Different Types of Subcutaneous Drug Delivery Systems
  • Figure 10.2 Subcutaneous Drug Delivery Systems: Distribution by Type of Delivery System
  • Figure 10.3 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Stage of Development
  • Figure 10.4 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Type of Device
  • Figure 10.5 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Type of Dose Administered
  • Figure 10.6 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Volume / Storage Capacity
  • Figure 10.7 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Usability
  • Figure 10.8 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Mode of Injection
  • Figure 10.9 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Mechanism of Action
  • Figure 10.10 Large Volume Wearable Injectors for Non-Insulin Biologics: Most Active Players
  • Figure 10.16 Large Volume Wearable Injectors for Non-Insulin Biologics: Product Competitiveness Analysis
  • Figure 10.12 Large Volume Wearable Injectors for Insulin: Distribution by Stage of Development
  • Figure 10.13 Large Volume Wearable Injectors for Insulin: Distribution by Type of Device
  • Figure 10.14 Large Volume Wearable Injectors for Insulin: Distribution by Volume / Storage Capacity
  • Figure 10.15 Large Volume Wearable Injectors for Insulin: Distribution by Usability
  • Figure 10.16 Large Volume Wearable Injectors for Insulin: Distribution by Availability of Integrated CGM / BGM System
  • Figure 10.17 Large Volume Wearable Injectors for Insulin: Most Active Players
  • Figure 10.18 Large Volume Wearable Injectors for Insulin: Product Competitiveness Analysis
  • Figure 10.19 Autoinjectors: Distribution by Usability
  • Figure 10.20 Autoinjectors: Distribution by Primary Container
  • Figure 10.21 Autoinjectors: Distribution by Volume / Storage Capacity
  • Figure 10.22 Autoinjectors: Distribution by Type of Dose
  • Figure 10.23 Autoinjectors: Distribution by Actuation Mechanism
  • Figure 10.24 Autoinjectors: Most Active Players
  • Figure 10.25 Autoinjectors: Product Competitiveness Analysis
  • Figure 10.26 Pen Injectors: Distribution by Usability
  • Figure 10.27 Pen Injectors: Distribution by Volume / Storage Capacity
  • Figure 10.28 Pen Injectors: Distribution by Type of Dose
  • Figure 10.29 Pen Injectors: Distribution by Most Active Players
  • Figure 10.30 Needle Free Injection Systems: Distribution by Stage of Development
  • Figure 10.31 Needle Free Injection Systems: Distribution by Volume / Storage Capacity
  • Figure 10.32 Needle Free Injection Systems: Distribution by Usability
  • Figure 10.33 Needle Free Injection Systems: Distribution by Actuation Mechanism
  • Figure 10.34 Needle Free Injection Systems: Most Active Players
  • Figure 10.35 Needle Free Injection Systems: Product Competitiveness Analysis
  • Figure 10.36 Novel Drug Reconstitution Systems: Distribution by Usability
  • Figure 10.37 Novel Drug Reconstitution Systems: Distribution by Type of Device
  • Figure 10.38 Novel Drug Reconstitution Systems: Distribution by Type of Drug Container
  • Figure 10.39 Novel Drug Reconstitution Systems: Most Active Players
  • Figure 10.40 Prefilled Syringes: Distribution by Barrel Fabrication Material
  • Figure 10.41 Prefilled Syringes: Distribution by Number of Barrel Chambers
  • Figure 10.42 Prefilled Syringes: Distribution by Type of Needle System
  • Figure 10.43 Prefilled Syringes: Distribution by Volume / Storage Capacity
  • Figure 10.44 Prefilled Syringes: Most Active Players
  • Figure 10.45 Prefilled Syringes: Product Competitiveness Analysis
  • Figure 10.46 Implants: Distribution by Stage of Development
  • Figure 10.47 Implants: Distribution by Target Therapeutic Area
  • Figure 10.48 Implants: Distribution by Implant Material
  • Figure 10.49 Implants: Distribution by Treatment Duration
  • Figure 10.50 Implants: Most Active Players
  • Figure 11.1 SWOT Analysis: Harvey Ball Analysis
  • Figure 11.2 Number of Biologics Approved by the FDA, 2011-2019
  • Figure 12.1 Overall Subcutaneous Biologics Market, 2020-2030 (USD Billion)
  • Figure 12.2 Subcutaneous Biologics Market: Distribution by Phase of Development, 2020-2030 (USD Billion)
  • Figure 12.3 Subcutaneous Biologics Market: Distribution by Type of Pharmacological Molecule, 2020-2030 (USD Billion)
  • Figure 12.4 Subcutaneous Biologics Market: Distribution by Target Therapeutic Area, 2020-2030 (USD Billion)
  • Figure 12.5 Subcutaneous Biologics Market: Distribution by Key Geographical Regions, 2020-2030 (USD Billion)
  • Figure 12.6 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2020-2030 (USD Million)
  • Figure 12.7 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2020-2030 (Units, Million)
  • Figure 12.8 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2020-2030 (USD Million)
  • Figure 12.9 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2020-2030 (Units, Million)
  • Figure 12.10 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2020-2030 (USD Million)
  • Figure 12.11 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2020-2030 (Units, Million)
  • Figure 12.12 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Target Therapeutic Area, 2020-2030 (USD Million)
  • Figure 12.13 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Target Therapeutic Area, 2020-2030 (Units, Million)
  • Figure 12.14 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Key Geographical Regions, 2020-2030 (USD Million)
  • Figure 12.15 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Key Geographical Regions, 2020-2030 (Units, Million)
  • Figure 12.16 Global Large Volume Wearable Injectors Market for Insulin , 2020-2030 (USD Million)
  • Figure 12.17 Global Large Volume Wearable Injectors Market for Insulin , 2020-2030 (Units, Million)
  • Figure 12.18 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, 2020-2030 (USD Million)
  • Figure 12.19 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, 2020-2030 (Units, Million)
  • Figure 12.20 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, 2020-2030 (USD Million)
  • Figure 12.21 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, 2020-2030 (Units, Million)
  • Figure 12.22 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Key Geographical Regions, 2020-2030 (USD Million)
  • Figure 12.23 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Key Geographical Regions, 2020-2030 (Units, Million)
  • Figure 12.24 Global Autoinjectors Market, 2020-2030 (USD Million)
  • Figure 12.25 Global Autoinjectors Market, 2020-2030 (Units, Million)
  • Figure 12.26 Global Autoinjectors Market: Distribution by Usability, 2020-2030 (USD Million)
  • Figure 12.27 Global Autoinjectors Market: Distribution by Usability, 2020-2030 (Units, Million)
  • Figure 12.28 Global Autoinjectors Market: Distribution by Type of Pharmacological Molecule, 2020-2030 (USD Million)
  • Figure 12.29 Global Autoinjectors Market: Distribution by Type of Pharmacological Molecule, 2020-2030 (Units, Million)
  • Figure 12.30 Global Autoinjectors Market: Distribution by Key Geographical Regions, 2020-2030 (USD Million)
  • Figure 12.31 Global Autoinjectors Market: Distribution by Key Geographical Regions, 2020-2030 (Units, Million)
  • Figure 12.32 Global Prefilled Syringes Market, 2020-2030 (USD Million)
  • Figure 12.33 Global Prefilled Syringes Market, 2020-2030 (Units, Million)
  • Figure 12.34 Global Prefilled Syringes Market: Distribution by Syringe Barrel Material, 2020-2030 (USD Million)
  • Figure 12.35 Global Prefilled Syringes Market: Distribution by Syringe Barrel Material, 2020-2030 (Units, Million)
  • Figure 12.36 Global Prefilled Syringes Market: Distribution by Type of Chamber System, 2020-2030 (USD Million)
  • Figure 12.37 Global Prefilled Syringes Market: Distribution by Type of Chamber System, 2020-2030 (Units, Million)
  • Figure 12.38 Global Prefilled Syringes Market: Distribution by Type of Pharmacological Molecule, 2020-2030 (USD Million)
  • Figure 12.39 Global Prefilled Syringes Market: Distribution by Type of Pharmacological Molecule, 2020-2030 (Units, Million)
  • Figure 12.40 Global Prefilled Syringes Market: Distribution by Target Therapeutic Area, 2020-2030 (USD Million)
  • Figure 12.41 Global Prefilled Syringes Market: Distribution by Target Therapeutic Area, 2020-2030 (Units, Million)
  • Figure 12.42 Global Prefilled Syringes Market: Distribution by Key Geographical Regions, 2020-2030 (USD Million)
  • Figure 12.43 Global Prefilled Syringes Market: Distribution by Key Geographical Regions, 2020-2030 (Units, Million)
  • Figure 12.44 Global Needle-Free Injection Systems Market, 2020-2030 (USD Million)
  • Figure 12.45 Global Needle-Free Injection Systems Market: Distribution by Usability, 2020-2030 (USD Million)
  • Figure 12.46 Global Needle-Free Injection Systems Market: Distribution by Actuation Mechanism, 2020-2030 (USD Million)
  • Figure 12.47 Global Needle-Free Injection Systems Market: Distribution by Target Therapeutic Area, 2020-2030 (USD Million)
  • Figure 12.48 Global Needle-Free Injection Systems Market: Distribution by Key Geographical Regions, 2020-2030 (USD Million)
  • Figure 12.49 Novel Drug Reconstitution Systems Market, 2020-2030 (USD Million)
  • Figure 12.50 Subcutaneous Formulation Technologies Market: Distribution by Upfront and Milestone Payments, 2020-2030 (USD Million)
  • Figure 13.1 Subcutaneous Biologics Market: Distribution by Type of Pharmacological Molecule, 2020, 2025, 2030 (USD Billion)

List Of Tables

  • Table 3.1 Comparison of Small Molecules and Biologics
  • Table 3.2 Parenteral Routes of Administration
  • Table 3.3 Parenteral Drug Formulations: Associated Physical and Chemical Instabilities
  • Table 3.4 Parenteral Drug Formulations: Key Excipients
  • Table 4.1 List of Approved Subcutaneous Biologics
  • Table 4.2 Approved Subcutaneous Biologics: Information on Targeted Indication and Therapeutic Area
  • Table 4.3 Approved Subcutaneous Biologics: Information on Dosing Frequency and Dosage Form
  • Table 4.4 List of Clinical-Stage Subcutaneous Biologics
  • Table 5.1 HUMIRA®: Approved Indications and Dosage Regimen
  • Table 5.2 Enbrel®: Approved Indications and Dosage Regimen
  • Table 5.3 RITUXAN® / MabThera®: Approved Indications and Therapy Type
  • Table 5.4 Comparison of Subcutaneous and Intravenous Formulations of RITUXAN® / MabThera®
  • Table 5.5 Herceptin®: Approved Indications and Therapy Type
  • Table 5.6 Comparison of Subcutaneous and Intravenous Formulations of Herceptin®
  • Table 5.7 Cost Comparison for Patients Treated with Intravenous Herceptin® and Subcutaneous Herceptin®
  • Table 5.8 Subcutaneous Herceptin® in Single-Use Injection Device: List of Clinical Trials
  • Table 6.1 Subcutaneous Formulation Technologies: List of Technology Developers
  • Table 6.2 Subcutaneous Formulation Technologies: Information on Type of Pharmacological Molecule
  • Table 6.3 Subcutaneous Formulation Technologies: Information on Route of Administration
  • Table 6.4 Subcutaneous Formulations Technologies: Information on Advantage(s) Offered
  • Table 7.1 Subcutaneous Formulation Technology Developers: Relative Scoring by Supplier Power, Pipeline Strength and Advantage(s) Offered
  • Table 8.1 Adocia: Product Portfolio
  • Table 8.2 Adocia: Recent Developments and Future Outlook
  • Table 8.3 Ajinomoto Althea: Recent Developments and Future Outlook
  • Table 8.4 Arecor: Product Portfolio
  • Table 8.5 Arecor: Recent Developments and Future Outlook
  • Table 8.6 Alteogen: Product Portfolio
  • Table 8.7 Alteogen: Recent Developments and Future Outlook
  • Table 8.8 Ascendis Pharma: Product Portfolio
  • Table 8.9 Ascendis Pharma: Recent Developments and Future Outlook
  • Table 8.10 Avadel Pharmaceuticals: Product Portfolio
  • Table 8.11 Avadel Pharmaceuticals: Recent Developments and Future Outlook
  • Table 8.12 Camurus: Product Portfolio
  • Table 8.13 Camurus: Recent Developments and Future Outlook
  • Table 8.14 Creative BioMart: Product Portfolio
  • Table 8.15 Creative BioMart: Recent Developments and Future Outlook
  • Table 8.16 Creative Biolabs: Product Portfolio
  • Table 8.17 Creative Biolabs: Recent Developments and Future Outlook
  • Table 8.18 DURECT: Product Portfolio
  • Table 8.19 DURECT: Recent Developments and Future Outlook
  • Table 8.20 Halozyme Therapeutics: Product Portfolio
  • Table 8.21 Halozyme Therapeutics: Recent Developments and Future Outlook
  • Table 8.22 MedinCell: Product Portfolio
  • Table 8.23 MedinCell: Recent Developments and Future Outlook
  • Table 8.24 Xeris Pharmaceuticals: Product Portfolio
  • Table 8.25 Xeris Pharmaceuticals: Recent Developments and Future Outlook
  • Table 8.26 Serina Therapeutics: Product Portfolio
  • Table 8.27 Serina Therapeutics: Recent Developments and Future Outlook
  • Table 9.1 Subcutaneous Formulation Technologies: List of Partnerships
  • Table 10.1 Subcutaneous Drug Delivery Systems: List of Key Players
  • Table 10.2 Large Volume Wearable Injectors: Development Landscape for Non-Insulin Biologics
  • Table 10.3 Large Volume Wearable Injectors: Development Landscape for Insulin
  • Table 10.4 Autoinjectors: Development Landscape
  • Table 10.5 List of Drug and Autoinjector Combination Products
  • Table 10.6 Pen Injectors: Development Landscape
  • Table 10.7 List of Drug and Pen Injector Combination Products
  • Table 10.8 Needle Free Injection Systems: Development Landscape
  • Table 10.9 Novel Drug Reconstitution Systems: Development Landscape
  • Table 10.10 Prefilled Syringe Systems: Development Landscape
  • Table 10.11 List of Glass Prefilled Syringes (Available in the Market)
  • Table 10.12 Plastic Prefilled Syringes (Available in the Market)
  • Table 10.13 List of Drugs Approved in Prefilled Syringes, 2013-2019
  • Table 10.14 Implants: Development Landscape
  • Table 15.1 Approved Subcutaneous Biologics: Distribution by Approval Year
  • Table 15.2 Approved Subcutaneous Biologics: Distribution by Type of Pharmacological Molecule
  • Table 15.3 Approved Subcutaneous Biologics: Distribution by Target Therapeutic Area
  • Table 15.4 Approved Subcutaneous Biologics: Distribution by Formulation
  • Table 15.5 Approved Subcutaneous Biologics: Distribution by Dosing Frequency
  • Table 15.6 Approved Subcutaneous Biologics: Distribution by Dosage For
  • Table 15.7 Key Players: Distribution by Number of Drugs Approved
  • Table 15.8 Clinical-Stage Subcutaneous Biologics: Distribution by Phase of Development
  • Table 15.9 Clinical-Stage Subcutaneous Biologics: Distribution by Type of Pharmacological Molecule
  • Table 15.10 Clinical-Stage Subcutaneous Biologics: Distribution by Target Therapeutic Area
  • Table 15.11 Clinical-Stage Subcutaneous Biologics: Distribution by Dosing Frequency
  • Table 15.12 Clinical-Stage Subcutaneous Biologics: Key Players
  • Table 15.13 Subcutaneous Biologics: Leading Drugs by Annual Sales, 2019 (USD Billion)
  • Table 15.14 HUMIRA®: Annual Sales, 2003-2019 (USD Billion)
  • Table 15.15 Enbrel®: Annual Sales in the US and Canada, 2002-2019 (USD Billion)
  • Table 15.16 Enbrel®: Annual Sales Outside US and Canada, 2010-2019 (USD Billion)
  • Table 15.17 RITUXAN® / MabThera®: Annual Sales, 1999-2019 (CHF Billion)
  • Table 15.18 Herceptin®: Annual Sales, 1999-2019 (CHF Billion)
  • Table 15.19 Neulasta®: Annual Sales, 2005-2019 (USD Billion)
  • Table 15.20 Subcutaneous Formulation Technologies: Distribution by Year of Establishment Technology Developers
  • Table 15.21 Subcutaneous Formulation Technologies: Distribution by Company Size of Technology Developers
  • Table 15.22 Subcutaneous Formulation Technologies: Distribution by Geographical Location of Technology Developers
  • Table 15.23 Subcutaneous Formulation Technologies: Distribution by Type of Pharmacological Molecule
  • Table 15.24 Subcutaneous Formulation Technologies: Distribution by Route of Administration
  • Table 15.25 Subcutaneous Formulation Technologies: Distribution by Advantage(s) Offered
  • Table 15.26 Adocia: Annual Revenues, 2014-2019 (EUR Million)
  • Table 15.27 Ajinomoto: Annual Revenues, FY1213-FY1819 (JPY Billion)
  • Table 15.28 Ascendis Pharma: Annual Revenues, 2012-Q3 2019 (EUR Million)
  • Table 15.29 Avadel Pharmaceuticals: Annual Revenues, 2013-2019 (USD Million)
  • Table 15.30 Camurus: Annual Revenues, 2013-2019 (SEK Million)
  • Table 15.31 Halozyme Therapeutics: Annual Revenues, 2009-2018 (USD Million)
  • Table 15.32 Subcutaneous Formulation Technology Partnerships: Distribution by Year of Partnership
  • Table 15.33 Subcutaneous Formulation Technology Partnerships: Distribution by Type of Partnership
  • Table 15.34 Most Active Players: Distribution by Number of Partnerships
  • Table 15.35 Subcutaneous Formulation Technology Partnerships: Regional Distribution
  • Table 15.36 Subcutaneous Formulation Technology Partnerships: Intercontinental and Intracontinental Agreements
  • Table 15.37 Subcutaneous Drug Delivery Systems: Overall Market Landscape by Number of Involved Players
  • Table 15.38 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Stage of Development
  • Table 15.39 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Type of Device
  • Table 15.40 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Type of Dose Administered
  • Table 15.41 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Volume / Storage Capacity
  • Table 15.42 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Usability
  • Table 15.43 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Mode of Injection
  • Table 15.44 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Mechanism of Action
  • Table 15.45 Large Volume Wearable Injectors for Non-Insulin Biologics: Most Active Players
  • Table 15.46 Large Volume Wearable Injectors for Insulin: Distribution by Stage of Development
  • Table 15.47 Large Volume Wearable Injectors for Insulin: Distribution by Type of Device
  • Table 15.48 Large Volume Wearable Injectors for Insulin: Distribution by Volume / Storage Capacity
  • Table 15.49 Large Volume Wearable Injectors for Insulin: Distribution by Usability
  • Table 15.50 Large Volume Wearable Injectors for Insulin: Distribution by Availability of Integrated CGM / BGM System
  • Table 15.51 Large Volume Wearable Injectors for Insulin: Most Active Players
  • Table 15.52 Autoinjectors: Distribution by Usability
  • Table 15.53 Autoinjectors: Distribution by Primary Container
  • Table 15.54 Autoinjectors: Distribution by Volume / Storage Capacity
  • Table 15.55 Autoinjectors: Distribution by Type of Dose
  • Table 15.56 Autoinjectors: Distribution by Actuation Mechanism
  • Table 15.57 Autoinjectors: Most Active Players
  • Table 15.58 Pen Injectors: Distribution by Usability
  • Table 15.59 Pen Injectors: Distribution by Volume / Storage Capcity
  • Table 15.60 Pen Injectors: Distribution by Type of Dose
  • Table 15.61 Pen Injectors: Most Active Players
  • Table 15.62 Needle Free Injection Systems: Distribution by Stage of Development
  • Table 15.63 Needle Free Injection Systems: Distribution by Volume / Storage Capacity
  • Table 15.64 Needle Free Injection Systems: Distribution by Usability
  • Table 15.65 Needle Free Injection Systems: Distribution by Actuation Mechanism
  • Table 15.66 Needle Free Injection Systems: Most Active Players
  • Table 15.67 Novel Drug Reconstitution Systems: Distribution by Usability
  • Table 15.68 Novel Drug Reconstitution Systems: Distribution by Device Type
  • Table 15.69 Novel Drug Reconstitution Systems: Distribution by Type of Drug Container
  • Table 15.70 Novel Drug Reconstitution Systems: Most Active Players
  • Table 15.71 Prefilled Syringes: Distribution by Barrel Fabrication Material
  • Table 15.72 Prefilled Syringes: Distribution by Number of Barrel Chambers
  • Table 15.73 Prefilled Syringes: Distribution by Type of Needle System
  • Table 15.74 Prefilled Syringes: Distribution by Volume / Storage Capacity
  • Table 15.75 Prefilled Syringes: Most Active Players
  • Table 15.76 Implants: Distribution by Stage of Development
  • Table 15.77 Implants: Distribution by Target Therapeutic Area
  • Table 15.78 Implants: Distribution by Implant Material
  • Table 15.79 Implants: Distribution by Treatment Duration
  • Table 15.80 Implants: Distribution by Most Active Players
  • Table 15.81 Number of Biologics Approved by the FDA, 2011-2019
  • Table 15.82 Subcutaneous Biologics Market, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Billion)
  • Table 15.83 Subcutaneous Biologics Market: Distribution by Phase of Development, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Billion)
  • Table 15.84 Subcutaneous Biologics Market: Distribution by Type of Pharmacological Molecule, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Billion)
  • Table 15.85 Subcutaneous Biologics Market: Distribution by Target Therapeutic Area, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Billion)
  • Table 15.86 Subcutaneous Biologics Market: Distribution by Key Geographical Regions, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Billion)
  • Table 15.87 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 15.88 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, Conservative, Base and Optimistic Scenario, 2020-2030 (Units, Million)
  • Table 15.89 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 15.90 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2020-2030 (Units, Million)
  • Table 15.91 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 15.92 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2020-2030 (Units, Million)
  • Table 15.93 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Target Therapeutic Area, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 15.94 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Target Therapeutic Area, Conservative, Base and Optimistic Scenario, 2020-2030 (Units, Million)
  • Table 15.95 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Key Geographical Regions, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 15.96 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Key Geographical Regions, Conservative, Base and Optimistic Scenario, 2020-2030 (Units, Million)
  • Table 15.97 Global Large Volume Wearable Injectors Market for Insulin, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 15.98 Global Large Volume Wearable Injectors Market for Insulin, Conservative, Base and Optimistic Scenario, 2020-2030 (Units, Million)
  • Table 15.99 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 15.100 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2020-2030 (Units, Million)
  • Table 15.101 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 15.102 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2020-2030 (Units, Million)
  • Table 15.103 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Key Geographical Regions, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 15.104 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Key Geographical Regions, Conservative, Base and Optimistic Scenario, 2020-2030 (Units, Million)
  • Table 15.105 Global Autoinjectors Market, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 15.106 Global Autoinjectors Market, Conservative, Base and Optimistic Scenario, 2020-2030 (Units, Million)
  • Table 15.107 Global Autoinjectors Market: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 15.108 Global Autoinjectors Market: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2020-2030 (Units, Million)
  • Table 15.109 Global Autoinjectors Market: Distribution by Type of Pharmacological Molecule, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 15.110 Global Autoinjectors Market: Distribution by Type of Pharmacological Molecule, Conservative, Base and Optimistic Scenario, 2020-2030 (Units, Million)
  • Table 15.111 Global Autoinjectors Market: Distribution by Key Geographical Regions, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 15.112 Global Autoinjectors Market: Distribution by Key Geographical Regions, Conservative, Base and Optimistic Scenario, 2020-2030 (Units, Million)
  • Table 15.113 Global Prefilled Syringes Market, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 15.114 Global Prefilled Syringes Market, Conservative, Base and Optimistic Scenario, 2020-2030 (Units, Million)
  • Table 15.115 Global Prefilled Syringes Market: Distribution by Syringe Barrel Material, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 15.116 Global Prefilled Syringes Market: Distribution by Syringe Barrel Material, Conservative, Base and Optimistic Scenario, 2020-2030 (Units, Million)
  • Table 15.117 Global Prefilled Syringes Market: Distribution by Type of Chamber System, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 15.118 Global Prefilled Syringes Market: Distribution by Type of Chamber System, Conservative, Base and Optimistic Scenario, 2020-2030 (Units, Million)
  • Table 15.119 Global Prefilled Syringes Market: Distribution by Type of Pharmacological Molecule, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 15.120 Global Prefilled Syringes Market: Distribution by Type of Pharmacological Molecule, Conservative, Base and Optimistic Scenario, 2020-2030 (Units, Million)
  • Table 15.121 Global Prefilled Syringes Market: Distribution by Target Therapeutic Area, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 15.122 Global Prefilled Syringes Market: Distribution by Target Therapeutic Area, Conservative, Base and Optimistic Scenario, 2020-2030 (Units, Million)
  • Table 15.123 Global Prefilled Syringes Market: Distribution by Key Geographical Regions, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 15.124 Global Prefilled Syringes Market: Distribution by Key Geographical Regions, Conservative, Base and Optimistic Scenario, 2020-2030 (Units, Million)
  • Table 15.125 Global Needle-Free Injection Systems Market, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 15.126 Global Needle-Free Injection Systems Market: Distribution by Product Usability, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 15.127 Global Needle-Free Injection Systems Market: Distribution by Actuation Mechanism, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 15.128 Global Needle-Free Injection Systems Market: Distribution by Target Therapeutic Area, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 15.129 Global Needle-Free Injection Systems Market: Distribution by Key Geographical Regions, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 15.130 Novel Drug Reconstitution Systems Market, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 15.131 Subcutaneous Formulation Technologies Market: Distribution by Type of Payment, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 15.132 Subcutaneous Biologics Market: Distribution by Type of Pharmacological Molecule, 2020, 2025, 2030 (USD Billion)

Listed Companies

The following companies and organizations have been mentioned in the report.

  • 1. 3D Medicines
  • 2. AB2 Bio
  • 3. Abbott Laboratories
  • 4. AbbVie
  • 5. Ablynx
  • 6. AC Immune
  • 7. Acceleron Pharma
  • 8. Accord Healthcare
  • 9. Acer Therapeutics
  • 10. ACG Management
  • 11. Activa Brand Products
  • 12. Adisave
  • 13. Adocia
  • 14. Affibody
  • 15. Affinivax
  • 16. Aguettant
  • 17. Aijex Pharma International
  • 18. Ajinomoto Bio-Pharma Services
  • 19. Akcea Therapeutics
  • 20. Akeso Tiancheng
  • 21. AKRA DERMOJET
  • 22. AktiVax
  • 23. Alder BioPharmaceuticals
  • 24. Alexion
  • 25. Alkermes
  • 26. Allergan
  • 27. Alnylam Pharmaceuticals
  • 28. Alopexx Oncology
  • 29. Alphamab
  • 30. Alteogen
  • 31. Altor BioScience
  • 32. ALTuCELL
  • 33. Altus Pharmaceuticals
  • 34. Alvogen
  • 35. ALZA
  • 36. AMAG Pharmaceuticals
  • 37. Amedra Pharmaceuticals
  • 38. Amgen
  • 39. Amgen Astellas BioPharma
  • 40. AnaptysBio
  • 41. Androsystems
  • 42. Antares Pharma
  • 43. Anterogen
  • 44. Anthera Pharmaceuticals
  • 45. Aphios
  • 46. Apobiologix
  • 47. Apotex
  • 48. Araclon Biotech
  • 49. Arecor
  • 50. argenx
  • 51. ARMO BioSciences
  • 52. Arsia Therapeutics
  • 53. ARTE
  • 54. Asahi Kasei
  • 55. Ascendis Pharma
  • 56. ASIT Biotech
  • 57. ASLAN Pharmaceuticals
  • 58. Aspen Pharmacare
  • 59. Astellas Pharma
  • 60. AstraZeneca
  • 61. Athyrium Capital Management
  • 62. Atridia
  • 63. Avadel Pharmaceuticals
  • 64. Avant Medical Corporation
  • 65. Avid Bioservices
  • 66. Avillion
  • 67. Axxia Pharmaceuticals
  • 68. BASF
  • 69. Bavarian Nordic
  • 70. Baxalta
  • 71. Bay City Capital
  • 72. Bayer
  • 73. Becton Dickinson
  • 74. Beijing Dongfang Biotech
  • 75. Beijing Northland Biotech
  • 76. Bespak
  • 77. Beta-Cell
  • 78. Beta-O2 Technologies
  • 79. Bill & Melinda Gates Foundation
  • 80. Bioam Gestion
  • 81. BioAtla
  • 82. BIOCAD
  • 83. Biocorp
  • 84. Biogen
  • 85. Bioject Medical Technologies
  • 86. BioMarin Pharmaceutical
  • 87. Biomay
  • 88. BioValve
  • 89. Bird Rock Bio
  • 90. Boehringer Ingelheim
  • 91. Boston Pharmaceuticals
  • 92. Braeburn Pharmaceuticals
  • 93. Bristol-Myers Squibb
  • 94. Britannia Pharmaceuticals
  • 95. Broadfin Capital
  • 96. Cadila Pharmaceuticals
  • 97. Calibr
  • 98. Cam Med
  • 99. Cambridge Antibody Technology
  • 100. Cambridge Consultants
  • 101. Camurus
  • 102. Carbion
  • 103. Catalyst Biosciences
  • 104. CDC Enterprises
  • 105. Celgene
  • 106. Celldex Therapeutics
  • 107. Cellnovo
  • 108. Central Texas Angel Network
  • 109. CeQur
  • 110. Chondrial Therapeutics
  • 111. Chugai Pharmaceutical
  • 112. CinnaGen
  • 113. Cleveland BioLabs
  • 114. CM-CIC Innovation
  • 115. College Diabetes Network
  • 116. Companion Medical
  • 117. Complex Biosystems
  • 118. Copernicus
  • 119. Corbion
  • 120. Corvidia Therapeutics
  • 121. Creative Biolabs
  • 122. Creative BioMart
  • 123. Crescendo Pharmaceuticals
  • 124. Crossject
  • 125. CSL Behring
  • 126. CSPC Pharmaceutical
  • 127. C-Tri
  • 128. Cumberland Pharmaceuticals
  • 129. CuraVac
  • 130. CytoDyn
  • 131. Cytori Therapeutics
  • 132. Daiichi Sankyo
  • 133. Daikyo Seiko
  • 134. DALI Medical Devices
  • 135. D'Antonio Consultants International
  • 136. Debiotech
  • 137. Deerfield Management
  • 138. Delpor
  • 139. DelSiTech
  • 140. Dermira
  • 141. Desentum
  • 142. DiaMedica Therapeutics
  • 143. Diamesco
  • 144. Diasome Pharmaceuticals
  • 145. Digital Medics
  • 146. Digna Biotech
  • 147. Dongbao
  • 148. Dr. Reddy's Laboratories
  • 149. DSM Venturing
  • 150. Duoject Medical Systems
  • 151. DURECT
  • 152. Dyax (acquired by Shire)
  • 153. Eagle Pharmaceuticals
  • 154. Eddingpharm
  • 155. Eiger BioPharmaceuticals
  • 156. Eisai
  • 157. Elcam Medical
  • 158. Elektrofi
  • 159. Eli Lilly
  • 160. EMD Serono
  • 161. Emergent BioSolutions
  • 162. Emperra
  • 163. Enable Injections
  • 164. Endo Pharmaceuticals
  • 165. Enesi Pharma
  • 166. EOC Pharma
  • 167. Epilepsy Foundation
  • 168. Etubics
  • 169. European Pharma Group
  • 170. Ever Supreme Bio Technology
  • 171. Excelse Bio
  • 172. EyeTech
  • 173. Felton International
  • 174. Ferring Pharmaceuticals
  • 175. Finox Biotech
  • 176. Flamel Technologies
  • 177. Flowonix Medical
  • 178. FluGen
  • 179. Fresenius Kabi
  • 180. FUJIFILM Diosynth Biotechnologies
  • 181. Future Injection Technologies
  • 182. Fuze
  • 183. GALVmed
  • 184. GC Pharma
  • 185. Genentech
  • 186. Generon
  • 187. Genexine
  • 188. Genmab
  • 189. Genor Biopharma
  • 190. GEROPHARM
  • 191. Gerresheimer
  • 192. Gilde Healthcare
  • 193. Gilead Sciences
  • 194. GlaxoSmithKline
  • 195. Globe Medical Tech
  • 196. GlobeImmune
  • 197. Grifols
  • 198. HAL Allergy
  • 199. Halozyme Therapeutics
  • 200. Hanall Biopharma
  • 201. Hanmi Pharmaceutical
  • 202. Harbour BioMed
  • 203. Haselmeier
  • 204. Health Decisions
  • 205. Hercules Capital
  • 206. Heron Therapeutics
  • 207. Hikma Pharmaceuticals
  • 208. Hospira
  • 209. Human Genome Sciences
  • 210. IDINVEST Partners
  • 211. ILTOO Pharma
  • 212. Il-Yang Pharmaceutical
  • 213. Immunex
  • 214. Immunomedics
  • 215. ImmunoVaccine Technologies
  • 216. ImmusanT
  • 217. Immutep
  • 218. Impax Laboratories
  • 219. Incepta Pharmaceuticals
  • 220. Indivior
  • 221. Injecto
  • 222. INJEX Pharma
  • 223. Inmunotek
  • 224. InnoCore Pharmaceuticals
  • 225. Innovare R&D
  • 226. Innovate UK
  • 227. Innovent Biologics
  • 228. Inolife Sciences
  • 229. Inovio Pharmaceuticals
  • 230. i-novion
  • 231. Insense
  • 232. Insulet
  • 233. Insuline Medical
  • 234. Intarcia Therapeutics
  • 235. Integrity Bio
  • 236. Intrexon
  • 237. Ipsen
  • 238. ISU Abxis
  • 239. Izana Bioscience
  • 240. Janssen
  • 241. Janus Capital
  • 242. JCR Pharmaceuticals
  • 243. JDRF
  • 244. Jiangsu Delfu Medical Device
  • 245. Jiangsu Hengrui Medicine
  • 246. Jiangsu Wan Hai Medical Instruments
  • 247. JO Pharma
  • 248. Johnson & Johnson
  • 249. Juvenile Diabetes Research Foundation
  • 250. Kaléo
  • 251. Kangstem Biotech
  • 252. Kastle Therapeutics
  • 253. KBI Biopharma
  • 254. Kedrion Biopharma
  • 255. King Pharmaceuticals
  • 256. Kingsbury Capital Partners
  • 257. Kitasato Daiichi Sankyo Vaccine
  • 258. Knight Therapeutics
  • 259. Kolltan Pharmaceuticals
  • 260. Kyowa Hakko Kirin
  • 261. Kyowa Kirin
  • 262. Laboratorios Liomont
  • 263. Lapeyronie Hospital
  • 264. Lenis Medical
  • 265. LEO Pharma
  • 266. Leukocare Biotechnology
  • 267. Lindy Biosciences
  • 268. Lineage Therapeutics
  • 269. Lundbeck
  • 270. Lupin
  • 271. Luye Pharma
  • 272. Manchester Institute of Biotechnology
  • 273. Maruho
  • 274. Maruishi Pharmaceutical
  • 275. Massachusetts Institute of Technology
  • 276. MaxiVAX
  • 277. McNair Group
  • 278. Medac Pharma
  • 279. Medical International Technology
  • 280. Medicalchain
  • 281. Medicom Innovation Partner
  • 282. MedImmune
  • 283. MedinCell
  • 284. Medipacs
  • 285. MedPro
  • 286. Medtronic
  • 287. Medtrum
  • 288. Merck
  • 289. Merieux Développement
  • 290. MGlas
  • 291. MicroVAX
  • 292. Mika Medical
  • 293. MilliporeSigma
  • 294. Miracle Medical
  • 295. Mitsubishi Gas Chemical
  • 296. Mitsubishi Tanabe Pharma
  • 297. MJ Biopharm
  • 298. Momenta Pharmaceuticals
  • 299. Morphogenesis
  • 300. MorphoSys
  • 301. Mylan
  • 302. Nano Precision Medical
  • 303. NantCell
  • 304. National Cancer Institute
  • 305. National Institute of Allergy and Infectious Diseases
  • 306. National Institute of Diabetes and Digestive and Kidney Diseases
  • 307. National Institute of Neurological Disorders and Stroke
  • 308. The National Medical Products Administration
  • 309. Nektar Therapeutics
  • 310. Nemera
  • 311. Neumedicines
  • 312. Neurimmune
  • 313. NeuroDerm
  • 314. NGM Biopharmaceuticals
  • 315. Ningbo Zhengli Pharmaceutical Packing
  • 316. Nippon Organon
  • 317. Nipro Medical
  • 318. Nordic Group
  • 319. Novartis
  • 320. Novimmune
  • 321. Novo Nordisk
  • 322. NPS Pharmaceuticals
  • 323. Nuance Designs
  • 324. Numab
  • 325. Nuova Ompi
  • 326. OBI Pharma
  • 327. Omeros
  • 328. Ompi
  • 329. Oncolix
  • 330. OPKO Health
  • 331. OrbiMed
  • 332. Orphan Technologies
  • 333. Otsuka Pharmaceutical
  • 334. Oval Medical Technologies
  • 335. Owen Mumford
  • 336. Oxford Finance
  • 337. PA Consulting
  • 338. Pacira BioSciences
  • 339. Palmetto Partners
  • 340. PaxVax
  • 341. Pendiq
  • 342. Penjet
  • 343. Pfizer
  • 344. PharmaJet
  • 345. Pharmakon Advisors
  • 346. PharmaSens
  • 347. Pharmstandard
  • 348. PhaseBio Pharmaceuticals
  • 349. PHC Injection Device Technologies
  • 350. Philogen
  • 351. Phoundry Pharmaceuticals
  • 352. Plas-Tech Engineering
  • 353. Polfa Tarchomin
  • 354. Population Council
  • 355. Portal Instruments
  • 356. Primequal
  • 357. ProJect Pharmaceutics
  • 358. Prolynx
  • 359. Promius Pharma
  • 360. ProteoThera
  • 361. Provenance Biopharmaceuticals
  • 362. Pulse NeedleFree Systems
  • 363. QS Medical Technology
  • 364. Qu Biologics
  • 365. RA Capital Management
  • 366. Receptos
  • 367. Recon Therapeutics
  • 368. Redmile Group
  • 369. ReForm Biologics
  • 370. Regeneron Pharmaceuticals
  • 371. REMD Biotherapeutics
  • 372. RemeGen
  • 373. Rentschler Biotechnologie
  • 374. Revolutions Medical
  • 375. Rhône-Poulenc Rorer
  • 376. RMS Medical Products
  • 377. Roche
  • 378. Rock Springs Capital
  • 379. Roselabs Bioscience
  • 380. ROXALL Medizin
  • 381. R-Pharm
  • 382. Sabby Management
  • 383. Salix Pharmaceuticals
  • 384. Samsung Bioepis
  • 385. Sandoz
  • 386. Sanofi
  • 387. Santen Pharmaceutical
  • 388. Schering-Plough
  • 389. Schott
  • 390. Scripps Research Institute
  • 391. Sensile Medical
  • 392. Seqirus
  • 393. Serina Therapeutics
  • 394. Sernova
  • 395. Serum Institute of India
  • 396. Sewa Medicals
  • 397. Shandong Pharmaceutical Glass
  • 398. Shandong Weigao
  • 399. Shandong Zibo Minkang Pharmaceutical Packing
  • 400. Shanghai Dahua Pharmaceutical
  • 401. Shanghai JMT-Bio
  • 402. Shanghai Junshi Biosciences
  • 403. Shanghai Umitai Medical Technology
  • 404. Shenzhen Salubris Pharmaceuticals
  • 405. Shin Yan Sheno Precision Industrial
  • 406. Shire
  • 407. SHL Medical
  • 408. Shreya Life Sciences
  • 409. Silicon Valley Bank
  • 410. Sinocelltech
  • 411. SiO2 Medical Products
  • 412. SK Chemicals
  • 413. Société Générale Asset Management
  • 414. Sofinnova Partners
  • 415. Solteam Medical
  • 416. SOOIL Development
  • 417. SOTIO
  • 418. Spectrum Pharmaceuticals
  • 419. Square Pharmaceuticals
  • 420. STADA Arzneimittel
  • 421. SteadyMed Therapeutics
  • 422. Stemirna Therapeutics
  • 423. Subcuject
  • 424. Sumitomo Dainippon Pharma
  • 425. Sun Pharmaceutical Industries
  • 426. Swedish Orphan Biovitrum
  • 427. Synermore Biologics
  • 428. Synthon Hispania
  • 429. Taisei Kako
  • 430. Taisho Pharmaceutical
  • 431. Takeda Pharmaceutical
  • 432. Talecris Biotherapeutics
  • 433. Tandem Diabetes Care
  • 434. Technical University of Munich
  • 435. Telegraph Hill Partners
  • 436. TerSera Therapeutics
  • 437. Terumo
  • 438. Teva Pharmaceuticals
  • 439. Texan Allergy & Sinus Center
  • 440. Texas Diabetes Institute
  • 441. Texas Emerging Technologies Fund
  • 442. The National Institute for Health and Care Excellence
  • 443. The National Medical Products
  • 444. The Wyss Institute at Harvard University
  • 445. TheraCyte
  • 446. Theralpha
  • 447. Tianjin SinoBiotech
  • 448. Titan Pharmaceuticals
  • 449. Tonghua Dongbao
  • 450. Torii Pharmaceutical
  • 451. Touche Medical
  • 452. Transcoject
  • 453. Transgene
  • 454. TREOS Bio
  • 455. Tyfill Pharmapack
  • 456. U.S. Medical Instruments
  • 457. UCB Pharma
  • 458. Ultragenyx Pharmaceutical
  • 459. Uman Pharma
  • 460. Uni-Bio Science Group
  • 461. Unilever
  • 462. Unilife
  • 463. Union Medico
  • 464. United BioPharma
  • 465. United Therapeutics
  • 466. University of Colorado
  • 467. University of Texas Health Science Center
  • 468. US WorldMeds
  • 469. Valeant Pharmaceuticals
  • 470. Valeritas
  • 471. Venrock
  • 472. Ventana Medical Systems
  • 473. Vetter Pharma
  • 474. ViaCyte
  • 475. ViCentra
  • 476. Viela Bio
  • 477. ViiV Healthcare
  • 478. ViroMed
  • 479. ViroPharma
  • 480. Vitaeris
  • 481. Vivo Capital
  • 482. Wanhai Medical
  • 483. West Pharmaceutical Services
  • 484. Wild Basin Investments
  • 485. XBiotech
  • 486. Xellia Pharmaceuticals
  • 487. XEME Biopharma
  • 488. Xencor
  • 489. Xeris Pharmaceuticals
  • 490. YangZhong Wealth Metal
  • 491. Youlyy Industrial
  • 492. Ypsomed
  • 493. Zensun
  • 494. Zogenix
  • 495. Zweite TechnoStart Ventures Fonds